We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
This second part of Drug Industry Daily’s two-part report on user fee reauthorization focuses on prospects for the Biosimilar User Fee Act and the Generic Drug User Fee Act.